<DOC>
	<DOCNO>NCT00950833</DOCNO>
	<brief_summary>The objective study evaluate immune memory administration additional dose GSK Biologicals ' pneumococcal conjugate vaccine GSK1024850A , antibody persistence long-term effect nasopharyngeal carriage S. pneumoniae H. influenzae subject prim boosted GSK Biologicals ' pneumococcal conjugate vaccine GSK1024850A previous primary booster study . For subject receive investigational vaccine primary booster study , objective evaluate immunogenicity , safety reactogenicity 2-dose catch-up vaccination GSK Biologicals ' pneumococcal conjugate vaccine GSK1024850A . This protocol post deal objective &amp; outcome measure extension phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT00370318 ) . The objective &amp; outcome measure booster phase present separate protocol posting ( NCT00496015 ) .</brief_summary>
	<brief_title>Long-term Follow-up Study Children Previously Primed With GSK Pneumococcal Vaccine ( GSK1024850A ) Unprimed Children</brief_title>
	<detailed_description>This protocol posting update accord Protocol Amendment 1 , July 2009</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/ guardian comply requirement protocol enrol study . A male female , include , 31 34 month age time enrolment . Subjects previously participate study NCT00496015 For subject prim APAP NAPpre group : subject receive booster dose pneumococcal conjugate vaccine prior study amendment 3 . For subject unprimed group : subject receive dose meningococcal vaccine GSK134612 . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede enrolment , plan use entire study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug entire study period . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose study vaccine end 30 day . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Any confirm suspect immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine . History seizures progressive neurological disease . Acute disease time enrolment , define presence mild , moderate severe illness without fever . Administration plan use immunoglobulin and/ blood product entire study period . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Subjects parent history atopia ( polinosis , asthma , atopic eczema ) . Administration pneumococcal vaccine since end study NCT00496015 .</criteria>
	<gender>All</gender>
	<minimum_age>31 Months</minimum_age>
	<maximum_age>44 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Catch-up vaccination</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Immune memory</keyword>
	<keyword>Nasopharyngeal carriage</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Safety</keyword>
</DOC>